| Antibodies to watch in 2022 H Kaplon, A Chenoweth, S Crescioli, JM Reichert MAbs 14 (1), 2014296, 2022 | 312 | 2022 |
| Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma DO Khair, HJ Bax, S Mele, S Crescioli, G Pellizzari, A Khiabany, ... Frontiers in immunology 10, 453, 2019 | 250 | 2019 |
| Antibodies to watch in 2023 H Kaplon, S Crescioli, A Chenoweth, J Visweswaraiah, JM Reichert MAbs 15 (1), 2153410, 2023 | 219 | 2023 |
| Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs) RM Hoffmann, BGT Coumbe, DH Josephs, S Mele, KM Ilieva, A Cheung, ... Oncoimmunology 7 (3), e1395127, 2018 | 174 | 2018 |
| Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action ZN Willsmore, BGT Coumbe, S Crescioli, S Reci, A Gupta, RJ Harris, ... European Journal of Immunology 51 (3), 544-556, 2021 | 155 | 2021 |
| IgG4 characteristics and functions in cancer immunity S Crescioli, I Correa, P Karagiannis, AM Davies, BJ Sutton, FO Nestle, ... Current allergy and asthma reports 16, 1-11, 2016 | 121 | 2016 |
| BRAF inhibitors: resistance and the promise of combination treatments for melanoma M Griffin, D Scotto, DH Josephs, S Mele, S Crescioli, HJ Bax, G Pellizzari, ... Oncotarget 8 (44), 78174, 2017 | 118 | 2017 |
| Chondroitin sulfate proteoglycan 4 and its potential as an antibody immunotherapy target across different tumor types KM Ilieva, A Cheung, S Mele, G Chiaruttini, S Crescioli, M Griffin, ... Frontiers in immunology 8, 1911, 2018 | 114 | 2018 |
| Anti-folate receptor alpha–directed antibody therapies restrict the growth of triple-negative breast cancer A Cheung, J Opzoomer, KM Ilieva, P Gazinska, RM Hoffmann, H Mirza, ... Clinical Cancer Research 24 (20), 5098-5111, 2018 | 85 | 2018 |
| Anti-folate receptor-α IgE but not IgG recruits macrophages to attack tumors via TNFα/MCP-1 signaling DH Josephs, HJ Bax, T Dodev, M Georgouli, M Nakamura, G Pellizzari, ... Cancer research 77 (5), 1127-1141, 2017 | 80 | 2017 |
| B cells and the humoral response in melanoma: the overlooked players of the tumor microenvironment G Chiaruttini, S Mele, J Opzoomer, S Crescioli, KM Ilieva, KE Lacy, ... Oncoimmunology 6 (4), e1294296, 2017 | 76 | 2017 |
| Antibodies to watch in 2024 S Crescioli, H Kaplon, A Chenoweth, L Wang, J Visweswaraiah, ... MAbs 16 (1), 2297450, 2024 | 72 | 2024 |
| AllergoOncology: opposite outcomes of immune tolerance in allergy and cancer E Jensen‐Jarolim, HJ Bax, R Bianchini, S Crescioli, TR Daniels‐Wells, ... Allergy 73 (2), 328-340, 2018 | 72 | 2018 |
| IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin L Saul, KM Ilieva, HJ Bax, P Karagiannis, I Correa, ... Scientific reports 6 (1), 29736, 2016 | 72 | 2016 |
| Tumor-infiltrating B lymphocyte profiling identifies IgG-biased, clonally expanded prognostic phenotypes in triple-negative breast cancer RJ Harris, A Cheung, JCF Ng, R Laddach, AM Chenoweth, S Crescioli, ... Cancer research 81 (16), 4290-4304, 2021 | 69 | 2021 |
| The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression A Becchetti, S Crescioli, F Zanieri, G Petroni, R Mercatelli, S Coppola, ... Science signaling 10 (473), eaaf3236, 2017 | 69 | 2017 |
| IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states G Pellizzari, C Hoskin, S Crescioli, S Mele, J Gotovina, G Chiaruttini, ... EBioMedicine 43, 67-81, 2019 | 67 | 2019 |
| B cells in patients with melanoma: implications for treatment with checkpoint inhibitor antibodies ZN Willsmore, RJ Harris, S Crescioli, K Hussein, H Kakkassery, D Thapa, ... Frontiers in Immunology 11, 622442, 2021 | 65 | 2021 |
| hERG1 channels regulate VEGF-A secretion in human gastric cancer: clinicopathological correlations and therapeutical implications O Crociani, E Lastraioli, L Boni, S Pillozzi, MR Romoli, M D'Amico, ... Clinical Cancer Research 20 (6), 1502-1512, 2014 | 65 | 2014 |
| Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes HJ Bax, J Chauhan, C Stavraka, A Santaolalla, G Osborn, A Khiabany, ... British Journal of Cancer 128 (2), 342-353, 2023 | 41 | 2023 |
